WO2014198123A1 - 一种r型白藜芦醇二聚体、其制备方法及其降血糖用途 - Google Patents
一种r型白藜芦醇二聚体、其制备方法及其降血糖用途 Download PDFInfo
- Publication number
- WO2014198123A1 WO2014198123A1 PCT/CN2014/000558 CN2014000558W WO2014198123A1 WO 2014198123 A1 WO2014198123 A1 WO 2014198123A1 CN 2014000558 W CN2014000558 W CN 2014000558W WO 2014198123 A1 WO2014198123 A1 WO 2014198123A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tvn
- phase
- compound
- pharmaceutically acceptable
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to the field of natural medicinal chemistry, and in particular to a resveratrol dimer (7R, 8R)-trara-S-viniferin, a preparation method thereof and use thereof for lowering blood sugar.
- Idle countercurrent chromatography is a new technique for separation and preparation based on the difference in partition coefficients between two mutually immiscible solvents.
- the countercurrent color is applied to the separation of the chiral compound, and it is not necessary to chemically bond the chiral reagent to the solid medium, and it is only necessary to add a suitable chiral reagent to the liquid stationary phase or the mobile phase.
- the same countercurrent chromatographic separation column can be used repeatedly for the separation of different chiral compounds by simply selecting the appropriate two-phase solvent system and chiral reagent.
- the same countercurrent column can be used for both chiral analysis and chiral preparative separation by adjusting the amount of chiral reagent added to the stationary or mobile phase.
- the compound traw-S-viniferin (TVN for short) is a resveratrol dimer:
- the compound isolated in natural medicine or traditional Chinese medicine is obtained in the form of a racemate.
- the racemic TVN can also be obtained by biotransformation of resveratrol with bitter melon peroxidase in the laboratory.
- the invention discloses an optical isomer of TVN, namely (7R,8R)-tra ⁇ -5-viniferi n of structural formula I, abbreviated as (R,R)-TVN, structure
- the invention also discloses a chiral preparation method of (7R,8R)-t-S- V inif e rin of formula I and its medical use.
- the chiral high-speed countercurrent chromatography (HSCCC) of the racemic TVN was used to obtain (7R,8R)-;wS-viniferin (1, (R,R)-TVN) and (7S,8S)-i wS-viniferin ( (S,S)-TVN) Two optically pure compounds.
- the resveratrol was biotransformed by bitter melon peroxidase, and the transformed product was subjected to silica gel column chromatography, washed with chloroform:methanol as an eluent, and subjected to preparative HPLC to obtain a TVN racemate.
- the TVN racemate is subjected to high-speed countercurrent chromatography to obtain two optically pure compounds of (R, R)-TVN and (S, S)-TVN.
- the TVN racemate is dissolved in a small amount of the upper phase to be injected into the sample cell, and at the same time, the data is collected and the target component is received by the peak.
- mice weight 22-25 go and is randomly divided into 6 groups, 10 animals in each group. Animals in each group were intragastrically administered for 12 hours after fasting. Normal control group: an equal volume of 0.5% CMC-Na solution was administered to the positive control;
- Negative control group an equal volume of 0.5% CMC-Na solution was administered to the positive control
- Acarbose group 0.5% CMC-Na solution was formulated into a suspension of 0.33 mg/mL acarbose 0.3 mL/l Og body weight;
- TVN racemate group 0.5% CMC-Na solution was formulated into 0.33 mg/ml TVN racemate suspension 0.3 ml/l Og body weight;
- (S, S)-TVN group 0.5% CMC-Na solution was formulated into 0.33 mg/ml (S, S)-TVN suspension 0.3 ml/lOg body;
- (R, R)-TV group 0.5% CMC-Na solution was formulated into 0.33 mg/ml (R, R)-TVN suspension 0.3 ml/lOg body weight;
- the blood glucose-lowering rate of the acarbose group and the TVN racemate group at 0.5 hours was compared with the negative control group by SPSS11.5 software. They were 18.97% and 13.98%, respectively, and P ⁇ 0.05, that is, there was a significant difference.
- Their blood glucose-lowering rate at 1 hour was 21.66% and 14.60%, respectively, compared with the negative control group, which was a significant difference.
- the glucose-lowering rate of the (R, R)-TVN group at 0.5 hours and 1 hour was 30.20 °/ compared with the negative control group. And 22.79%, and P ⁇ 0.01, there is a very significant difference.
- the glucose-lowering rate at 0.5 hour and one hour was 0.08% and 3.01%, respectively, compared with the negative control group, and almost no difference from the negative control group.
- the glucose tolerance was measured at the overall level of the experiment by calculating the area under the sucrose tolerance test curve, compared with the negative control group, the TVN racemate group, the (R, R)-TVN group, and the negative control group.
- the area under the tolerance curve was 18.3, 16.7, and LI 21.0 mmol h/L, respectively, and PO.01, which is extremely significant.
- the area under the glucose tolerance curve of the (S, S)-TVN group was 20.9 mmoll/L, which was almost indistinguishable from the negative control group.
- Figure 1 is a plot of the area under the glucose tolerance curve of the experimental group. P ⁇ 0.05, "**": P ⁇ 0.01 (relative to the negative control group)
- Figure 2 is a high-speed countercurrent splitting diagram of the TVN racemate
- Figure 3 is a HPLC diagram of the TVN racemate and HSCCC fractions.
- Figure 4 is a CD diagram of two streams of HSCCC.
- phase solvent is used as the mobile phase, and then the lower phase is injected into the constant velocity countercurrent at a flow rate of l mJL/min, and the sample solution is injected into the sample cell when a significant lower phase exits at the outlet of the pipeline.
- the fractions were collected under UV detection at 313 nm.
- the countercurrent plot is shown in Figure 2, where: 1 is (S,S)-TVN and 2 is (R,R)-TVN.
- FIG. 3 (a) is the TVN racemic: (b) HSCCC contains (S, S)-TVN fractions; (c) HSCCC contains (R, R)-TVN fractions.
- HPLC conditions Agilent 1200 The HPLC was equipped with an Agilent HPLC workstation with an Agilent Zorbax SB-C 18 column (4.6 mm x 250 mm, 5 ⁇ ) at a temperature of 30 °C and a mobile phase of: 25 mmol L _1 ⁇ - ⁇ -CD in water: acetonitrile (75: 25, v/v), flow rate: 1.0 mL min" 1 , detection wavelength is 320 nm.
- Figure 4 shows the circular dichroism (CD) of two compounds, the CD curves of which are almost completely symmetrical at the same concentration.
- dashed line HSCCC contains CD map of (S,S)-TVN fraction
- solid line HSCCC contains CD map of (R, R)-TVN fraction
- concentration is 0.2 mg/ml o
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14811092.7A EP3009429B1 (en) | 2013-06-14 | 2014-06-05 | R type resveratrol dimer, preparation method therefor and use thereof in reducing blood sugar |
JP2016518821A JP6364479B2 (ja) | 2013-06-14 | 2014-06-05 | R型レスベラトロール二量体の調製方法 |
US15/024,858 US9822089B2 (en) | 2013-06-14 | 2014-06-05 | R type of resveratrol dimer, preparation process therefor and purpose thereof in lowering blood sugar level |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310238137.6 | 2013-06-14 | ||
CN201310238137.6A CN103275044B (zh) | 2013-06-14 | 2013-06-14 | 一种r型白藜芦醇二聚体、其制备方法及其降血糖用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014198123A1 true WO2014198123A1 (zh) | 2014-12-18 |
Family
ID=49057691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/000558 WO2014198123A1 (zh) | 2013-06-14 | 2014-06-05 | 一种r型白藜芦醇二聚体、其制备方法及其降血糖用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9822089B2 (zh) |
EP (1) | EP3009429B1 (zh) |
JP (1) | JP6364479B2 (zh) |
CN (1) | CN103275044B (zh) |
WO (1) | WO2014198123A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103275044B (zh) | 2013-06-14 | 2015-01-14 | 中国药科大学 | 一种r型白藜芦醇二聚体、其制备方法及其降血糖用途 |
CN103524594B (zh) * | 2013-10-16 | 2015-04-22 | 中国药科大学 | 高速逆流色谱从藜芦属植物中分离环巴胺类似物的方法 |
CN107536826B (zh) * | 2017-08-21 | 2021-03-05 | 陕西医药控股医药研究院有限公司 | 自组装法制备白藜芦醇二聚体δ-viniferin纳米制剂的方法 |
WO2020071541A1 (ja) * | 2018-10-04 | 2020-04-09 | 株式会社ホソダShc | 腸内細菌叢改善組成物 |
CN109700796A (zh) * | 2019-03-02 | 2019-05-03 | 中国科学院昆明植物研究所 | 芍药籽中寡聚芪类化合物在制药中的应用 |
CN112791080B (zh) * | 2021-01-21 | 2022-11-08 | 中国药科大学 | 白藜芦醇二聚体tvn在制备治疗骨性关节炎的药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101433534A (zh) | 2008-12-22 | 2009-05-20 | 中国药科大学 | 白藜芦醇二聚体用于制备降血糖药物的用途 |
CN101977601A (zh) * | 2007-11-15 | 2011-02-16 | 泰奥索公司 | 茋类多酚衍生物的组合物及其用于对抗活生物体的病理学状态和衰老的应用 |
CN103275044A (zh) * | 2013-06-14 | 2013-09-04 | 中国药科大学 | 一种r型白藜芦醇二聚体、其制备方法及其降血糖用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012506912A (ja) * | 2008-11-04 | 2012-03-22 | ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | アテローム硬化症、メタボリックシンドロームおよびそれらの症状を予防および処置するためのd−タガトースベースの組成物および方法 |
CN101979617B (zh) * | 2010-10-12 | 2012-10-03 | 尉亚辉 | 白藜芦醇二聚体的制备方法 |
-
2013
- 2013-06-14 CN CN201310238137.6A patent/CN103275044B/zh not_active Expired - Fee Related
-
2014
- 2014-06-05 US US15/024,858 patent/US9822089B2/en active Active
- 2014-06-05 WO PCT/CN2014/000558 patent/WO2014198123A1/zh active Application Filing
- 2014-06-05 EP EP14811092.7A patent/EP3009429B1/en not_active Not-in-force
- 2014-06-05 JP JP2016518821A patent/JP6364479B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101977601A (zh) * | 2007-11-15 | 2011-02-16 | 泰奥索公司 | 茋类多酚衍生物的组合物及其用于对抗活生物体的病理学状态和衰老的应用 |
CN101433534A (zh) | 2008-12-22 | 2009-05-20 | 中国药科大学 | 白藜芦醇二聚体用于制备降血糖药物的用途 |
CN103275044A (zh) * | 2013-06-14 | 2013-09-04 | 中国药科大学 | 一种r型白藜芦醇二聚体、其制备方法及其降血糖用途 |
Also Published As
Publication number | Publication date |
---|---|
US20160229828A1 (en) | 2016-08-11 |
EP3009429A4 (en) | 2016-11-23 |
CN103275044A (zh) | 2013-09-04 |
US9822089B2 (en) | 2017-11-21 |
EP3009429B1 (en) | 2017-12-06 |
JP2016521729A (ja) | 2016-07-25 |
CN103275044B (zh) | 2015-01-14 |
EP3009429A1 (en) | 2016-04-20 |
JP6364479B2 (ja) | 2018-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014198123A1 (zh) | 一种r型白藜芦醇二聚体、其制备方法及其降血糖用途 | |
US20130317249A1 (en) | Method for the purification of prostaglandins | |
CN106770807A (zh) | 一种氟比洛芬酯注射液中有关物质的检测方法 | |
CN105954447B (zh) | 一种通过hplc分析分离苯甲酰科立内酯对映异构体的方法 | |
Zhang et al. | Separation of amlodipine besilate enantiomers by biphasic recognition recycling high-speed counter-current chromatography | |
CN111533695B (zh) | 一种依托咪酯的制备方法 | |
CN105784878B (zh) | 一种hplc法分析分离顺式双环[3,2,0]庚‑2‑烯‑6‑酮对映异构体的方法 | |
WO2008062468A2 (en) | Process for the preparation of optically pure indeno [5,4-b] furan derivatives | |
TW201542522A (zh) | 吡咯衍生物之製造方法及其中間體 | |
CN103760286A (zh) | 一种用高效液相色谱法测定琥珀酸索非那新中间体光学纯度的方法 | |
CN110646533A (zh) | 一种氟比洛芬酯药品中有关物质的检测方法 | |
CN101881755B (zh) | 通过高效液相色谱法检测盐酸艾司洛尔光学异构体的方法 | |
CN109580833B (zh) | 一种西格列汀原料及制剂中对映异构体杂质的测定方法 | |
RU2667002C1 (ru) | Способ селективного разделения рацемической смеси сальбутамола | |
CN107235842B (zh) | 一种苯丙酸酯衍生物及其制备方法和应用 | |
CN102093272B (zh) | 消旋卡多曲化合物及其制法 | |
WO2009109792A1 (en) | New chiral stationary phases for chromatography based on aromatic allyl amines | |
CN109406685B (zh) | 一种分离卡非佐米和其异构体的高效液相色谱方法 | |
CN108956808B (zh) | 一种hplc法分析及制备双乙酰科立内酯对映异构体的方法 | |
CN106974921B (zh) | 2R-cardiospermin-5-p-hydroxybenzoate的制备及其在制备治疗类风湿关节炎药物中的应用 | |
CN111999405A (zh) | 一种氟比洛芬酯与去氟氟比洛芬酯的分离检测方法 | |
WO2019184194A1 (zh) | 地黄素的制备、分析和细胞免疫治疗用途 | |
JP3316234B2 (ja) | 新規なn−(4−エトキシフエニル)−3−ヒドロキシブタナミドの光学活性体 | |
US8420819B2 (en) | Process for optimizing the particle size of an active pharmaceutical ingredient by crystallization | |
CN106974922B (zh) | 2S-cardiospermin-5-cis-p-coumarate的制备及其在制备治疗类风湿关节炎药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2016518821 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014811092 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14811092 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15024858 Country of ref document: US |